All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists vs Sodium–Glucose Cotransporter-2 Inhibitors
Authors:
- Samita GargSGSamita Garg
- Thabet QapajaTQThabet Qapaja
- Osama HamidOHOsama Hamid
- Gizem KayaGKGizem Kaya
- Rashid Abdel-RazeqRARashid Abdel-Razeq
- Dina AlayanDADina Alayan
- Mohammed Abu-RumailehMAMohammed Abu-Rumaileh
- Anthony LemboALAnthony Lembo
- Steven NissenSNSteven Nissen
Open Access
- 4 July 2025
- journal article
- Published by Elsevier in Gastro Hep Advances
- Vol. 4 (10)
Abstract
No abstract availableKeywords
Funding Information
- Abbott Pharmaceuticals
This publication has 24 references indexed in Scilit:
- The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitisDiabetes Research and Clinical Practice, 2024
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight LossJAMA, 2023
- Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2023
- Association between glucagon‐like peptide‐1 receptor agonists and biliary‐related diseases in patients with type 2 diabetes: A nationwide cohort studyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2022
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary DiseasesJAMA Internal Medicine, 2022
- Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 DiabetesClinical Pharmacology & Therapeutics, 2021
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trialsEndocrine, 2020
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet Diabetes & Endocrinology, 2019
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes MellitusJAMA Internal Medicine, 2013